絞り込み

16646

広告

Tau Oligomers as Potential Targets for Alzheimer's Diagnosis and Novel Drugs.

著者 Guzmán-Martinez L , Farías GA , Maccioni RB
Front Neurol.2013 ; 4():167.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Laboratory of Cellular and Molecular Neurosciences, Faculty of Sciences, University of Chile , Santiago , Chile ; International Center for Biomedicine (ICC) , Santiago , Chile.

スターを付ける スターを付ける     (3view , 0users)

Full Text Sources

Miscellaneous

A cumulative number of approaches have been carried out to elucidate the pathogenesis of Alzheimer's disease (AD). Tangles formation has been identified as a major event involved in the neurodegenerative process, due to the conversion of either soluble peptides or oligomers into insoluble filaments. Most of recent studies share in common the observation that formation of tau oligomers and the subsequent pathological filaments arrays is a critical step in AD etiopathogenesis. Oligomeric tau species appear to be toxic for neuronal cells, and therefore appear as an appropriate target for the design of molecules that may control morphological and functional alterations leading to cognitive impairment. Thus, current therapeutic strategies are aimed at three major types of molecules: (1) inhibitors of protein kinases and phosphatases that modify tau and that may control neuronal degeneration, (2) methylene blue, and (3) natural phytocomplexes and polyphenolics compounds able to either inhibit the formation of tau filaments or disaggregate them. Only a few polyphenolic molecules have emerged to prevent tau aggregation. In this context, fulvic acid (FA), a humic substance, has potential protective activity cognitive impairment. In fact, formation of paired helical filaments in vitro, is inhibited by FA affecting the length of fibrils and their morphology.
PMID: 24191153 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード